NCT05069558进行中（未招募）不适用
Prospective Randomized Multi-center Controlled Clinical Investigation Comparing Patent Foramen Ovale (PFO) Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 450
- 试验地点
- 94
- 主要终点
- Effective Closure Rate of PFO
研究概览
简要总结
The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/procedure related Serious Adverse Events (SAE).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with a PFO and cryptogenic stroke:
- •PFO defined as visualization of microbubbles (during Trans Esophageal Echo (TEE)) in the left atrium within three cardiac cycles of right atrial opacification at rest and/or with Valsalva.
- •Cryptogenic stroke defined as a stroke of unknown cause.
- •Stroke defined as an acute focal neurological deficit, presumed to be due to focal ischemia, and either:
- •Symptoms persisting ≥24 hours OR
- •Symptoms persisting <24 hours with Magnetic Resonance Imaging (MRI) or Computer Tomography (CT) findings of a new, neuroanatomically relevant, cerebral infarct.
排除标准
- •Age < 18 years
- •Myocardial Infarction (MI) or unstable angina within 6 months.
- •Severe mitral valve stenosis, severe aortic valve stenosis, or severe regurgitation.
- •Left Ventricle Ejection Fraction (LVEF) <35%.
- •Uncontrolled hypertension or diabetes mellitus despite medications.
- •Subjects contraindicated for aspirin or clopidogrel.
- •Presence of other comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results.
- •Qualifying stroke with Modified Rankin score >
- •Anatomy in which the device would interfere with intracardiac or vascular structures.
- •Life expectancy < 2 years.
- •Participation in another clinical study that can interfere with the results of this study
- •Exclusion for patients with known causes of ischemic stroke:
- •Atrial fibrillation/atrial flutter (chronic or intermittent).
- •Left Ventricle (LV) aneurysm, intracardiac thrombus, or tumor.
- •Mitral or aortic valve vegetation or prosthesis.
- •Aortic arch plaques protruding >4 mm into the lumen.
- •Atherosclerosis or arteriopathy of intra- or extracranial vessels with >50% diameter stenosis in the artery supplying the infarcted territory.
- •Another cause of right-to-left shunting (e.g., an Atrial Septal Defect (ASD) or a fenestrated atrial septum).
- •Presence of an arterial hypercoagulable state.
- •Lacunar infarct probably due to intrinsic small vessel as the qualifying event, defined as an ischemic stroke in the distribution of a single, small deep penetrating vessel in a patient with any of the following:
- •A history of hypertension (except in the first week post stroke).
- •A history of diabetes mellitus.
- •Age ≥50 years.
- •MRI or CT with leukoaraiosis greater than symmetric, well-defined periventricular caps, or bands (European Task Force on Age-Related White Matter Changes rating scale score >0).
- •Arterial dissection as the qualifying event.
研究组 & 干预措施
Investigational PFO Closure Device
Experimental
PFO closure with the study Occlutech Flex II PFO device.
干预措施: Investigational PFO Closure Device (Device)
Standard of Care PFO Closure Device
Active Comparator
PFO closure with either of the standard of care PFO occlusion devices; Amplatzer PFO Occluder or the Gore Cardioform PFO Occluder.
干预措施: Standard of Care PFO Closure Device (Device)
结局指标
主要结局
Effective Closure Rate of PFO
时间窗: Twelve Months
次要结局
- Non-Fatal Recurrent Stroke(Enrollment to 12 Months)
研究者
研究点 (94)
Loading locations...
相似试验
已完成
不适用
Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT TrialCryptogenic StrokeNCT00465270Abbott Medical Devices980
招募中
不适用
Encore PFO Closure Device - The PerFOrm TrialCryptogenic StrokePatent Foramen OvaleNCT05537753Encore Medical Inc.500
Unknown
2 期
MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair ImplantAuraMigrainePatent Foramen OvaleNCT00283738NMT Medical610
撤回
不适用
Close Obstructive Sleep Apnea (OSA) TrialObstructive Sleep ApneaPatent Foramen OvaleNCT06113562University of Miami60
招募中
不适用
CeraFlex PFO Closure System PMCF StudyPatent Foramen OvaleNCT06120270Lifetech Scientific (Shenzhen) Co., Ltd.180